CytomX Q2 revenue $24.7M (up 91% YoY); cash runway into H2 2025 after $30M financing

CytomX Therapeutics, Inc.

Cash, equivalents & investments $180.9M at June 30, 2023; $30M gross financing from BVF closed July 2023.
Revenue $24.7M (vs $12.9M Q2 2022) driven by BMS collaboration; R&D expenses fell to $20.7M.
CX-904 (EGFRxCD3) Phase 1 dose escalation data anticipated first half of 2024; backfill cohorts by end 2023.
IND filings for wholly-owned CX-2051 (EpCAM ADC) and CX-801 (IFNa2b) expected Q4 2023.
Appointed Dr. Wayne Chu as CMO; promoted Dawn Benson to SVP Quality and Product Manufacturing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CytomX Therapeutics, Inc. reported financial results for second quarter 2023.

Period: second quarter 2023
Result: reported results

Exact text from the filing

On August 8, 2023, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results as of and for the three and six months ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-039793

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.